Man Group plc bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 310,617 shares of the biopharmaceutical company's stock, valued at approximately $18,749,000. Man Group plc owned approximately 0.32% of Xenon Pharmaceuticals at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Xenon Pharmaceuticals during the second quarter worth about $454,057,000. Siren L.L.C. boosted its stake in shares of Xenon Pharmaceuticals by 62.2% in the first quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company's stock valued at $76,674,000 after purchasing an additional 505,803 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Xenon Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company's stock valued at $23,035,000 after purchasing an additional 8,980 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Xenon Pharmaceuticals by 13.8% in the fourth quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company's stock valued at $57,910,000 after purchasing an additional 156,820 shares in the last quarter. Finally, Castleark Management LLC purchased a new stake in Xenon Pharmaceuticals during the 1st quarter worth approximately $3,754,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director directly owned 1,870 shares in the company, valued at $119,792.20. This represents a 84.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 12,512 shares of company stock valued at $774,088. Corporate insiders own 2.91% of the company's stock.
Xenon Pharmaceuticals Price Performance
NASDAQ:XENE opened at $61.93 on Friday. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The firm has a market capitalization of $5.99 billion, a PE ratio of -13.07 and a beta of 0.62. The business's fifty day moving average price is $63.04 and its 200 day moving average price is $56.36.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same period in the previous year, the company earned ($1.07) EPS. As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the stock. Wells Fargo & Company reiterated an "overweight" rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. JPMorgan Chase & Co. boosted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 27th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Royal Bank Of Canada reduced their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a research note on Friday, August 7th. Finally, Needham & Company LLC decreased their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $77.13.
Check Out Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Featured Stories
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
